

ARTRYA™

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT MARKET RELEASE

12 March 2025

Issue of Shares on Conversion of Performance Rights

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, advises that on 11 March 2025, 25,000 ordinary shares were issued on the exercise and conversion of vested employee incentive performance rights.

An Appendix 2A seeking quotation of the shares, will be lodged following this announcement.

This announcement was approved by the Board.

For further information please contact:

Investor

Danny Younis

+61 420 293 042

danny.younis@automicgroup.com.au

Media

Rama Razy

+61 498 440 142

rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

Artrya Limited
ACN 624 005 741
1257 Hay Street West Perth WA 6005
PO Box 567 West Perth WA 6872
www.artrya.com
T: +61 8 6478 7816